Chiasma’s (CHMA) Buy Rating Reaffirmed at HC Wainwright

Chiasma (NASDAQ:CHMA)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They currently have a $11.00 price objective on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 109.52% from the company’s previous close.

CHMA has been the topic of a number of other research reports. Zacks Investment Research lowered shares of Chiasma from a “buy” rating to a “hold” rating in a report on Monday, October 14th. Brookline Capital Management reaffirmed a “buy” rating on shares of Chiasma in a research note on Wednesday, July 24th. Piper Jaffray Companies assumed coverage on shares of Chiasma in a research note on Wednesday, July 31st. They set an “overweight” rating and a $11.00 target price on the stock. ValuEngine lowered shares of Chiasma from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Finally, Cantor Fitzgerald set a $18.00 target price on shares of Chiasma and gave the company a “buy” rating in a research note on Friday, September 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Chiasma presently has a consensus rating of “Buy” and a consensus price target of $12.30.

Shares of Chiasma stock traded down $0.10 on Thursday, hitting $5.25. 124,000 shares of the company traded hands, compared to its average volume of 373,420. The company has a market cap of $225.72 million, a P/E ratio of -4.10 and a beta of 1.19. Chiasma has a 12-month low of $2.11 and a 12-month high of $9.25. The firm’s 50-day simple moving average is $5.13 and its 200 day simple moving average is $5.95.

Chiasma (NASDAQ:CHMA) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.01. Research analysts forecast that Chiasma will post -1.04 EPS for the current year.

In other news, Director Roni Mamluk sold 50,000 shares of Chiasma stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $5.59, for a total transaction of $279,500.00. Following the sale, the director now owns 50,000 shares of the company’s stock, valued at approximately $279,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Scott Minick bought 9,818 shares of the business’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $5.19 per share, for a total transaction of $50,955.42. Following the purchase, the director now directly owns 62,531 shares in the company, valued at approximately $324,535.89. The disclosure for this purchase can be found here. Insiders have bought a total of 17,268 shares of company stock worth $96,823 in the last ninety days. Insiders own 8.30% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Fosun International Ltd bought a new stake in Chiasma during the second quarter worth about $923,000. Vanguard Group Inc. boosted its stake in Chiasma by 30.9% during the second quarter. Vanguard Group Inc. now owns 1,051,908 shares of the biotechnology company’s stock worth $7,858,000 after acquiring an additional 248,574 shares in the last quarter. Strs Ohio bought a new stake in Chiasma during the second quarter worth about $560,000. Vivo Capital LLC bought a new stake in Chiasma during the second quarter worth about $17,758,000. Finally, Invesco Ltd. bought a new stake in Chiasma during the second quarter worth about $186,000. 53.00% of the stock is currently owned by institutional investors and hedge funds.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

See Also: Put Option

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit